Interested in Lifecore Biomedical, Inc.? Here are five stocks we like better.
Lifecore reaffirmed its 2026 guidance for revenue of $120 million to $125 million and adjusted EBITDA of $20.5 million to $25 million, despite second-quarter revenue falling 6.2% year over year to $34.2 million and the net loss widening to $6.2 million.
Contractually committed fill-finish demand from the company's largest customer is expected to double beginning in 2027 and exceed 2026 levels by more than 200% in 2028. Lifecore also completed a ***** anese regulatory inspection without material issues, potentially expanding market access.
Lifecore added six development programs during the quarter and now has 11 programs that could commercialize by the end of 2028. Management expects stronger second-half results, supported by higher aseptic and development revenue, while targeting roughly $7 million to $10 million in full-year free cash flow.
Lifecore Biomedical (NASDAQ:LFCR) reaffirmed its 2026 revenue and adjusted EBITDA guidance while outlining plans to support sharply higher fill-finish demand from its largest customer beginning in 2027.
#lifecore
Lifecore reaffirmed its 2026 guidance for revenue of $120 million to $125 million and adjusted EBITDA of $20.5 million to $25 million, despite second-quarter revenue falling 6.2% year over year to $34.2 million and the net loss widening to $6.2 million.
Contractually committed fill-finish demand from the company's largest customer is expected to double beginning in 2027 and exceed 2026 levels by more than 200% in 2028. Lifecore also completed a ***** anese regulatory inspection without material issues, potentially expanding market access.
Lifecore added six development programs during the quarter and now has 11 programs that could commercialize by the end of 2028. Management expects stronger second-half results, supported by higher aseptic and development revenue, while targeting roughly $7 million to $10 million in full-year free cash flow.
Lifecore Biomedical (NASDAQ:LFCR) reaffirmed its 2026 revenue and adjusted EBITDA guidance while outlining plans to support sharply higher fill-finish demand from its largest customer beginning in 2027.
#lifecore
3 months ago
